

Akuta N, <u>Suzuki F</u> , Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H	Extending combination therapy with peginterferon plus ribavirin for genotype 2 chronic hepatitis C virological responders: a pilot study of 7 cases.	Intervirol	53	188-192	2010
Arase Y, <u>Suzuki F</u> , Akuta N, Sezaki H, Suzuki Y, Kawamura Y, Kobayashi M, Hosaka T, Yatsuji H, Hirakawa M, Saitoh S, Ikeda K, Kobayashi M, Kumada H.	Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 1b and high virus load.	Int Med	49	957-963	2010
<u>Suzuki F</u> , Akuta N, Suzuki Y, Yatsuji H, Sezaki H, Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Watahiki S, Kumada H.	The efficacy of switching to entecavir monotherapy in Japanese lamivudine- pretreated patients.	Hepatol Res	25	892-898	2010
Hosaka T, <u>Suzuki F</u> , Kobayashi M, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.	HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy.	Liv Int	93	109-112	2010
Kawamura Y, Ikeda K, Hirakawa M, Yatsuji H, Hosaka T, Sezaki H, Kobayashi M, Kobayashi M, <u>Suzuki F</u> , Suzuki Y, Arase Y, Kumada H.	New classification of dynamic computed tomography images predictive of malignant characteristics of hepatocellular carcinoma.	Hepatol Res	40	1006-1014	2010
Ikeda K, Kobayashi M, Seko Y, Imai N, Hirakawa M, Kawamura Y, Sezaki H, Akuta N, <u>Suzuki F</u> , Suzuki Y, Saitoh S, Arase Y, Kumada H.	Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: A retrospective study of hepatitis C virus-related liver cancer.	Hepatol Res	40	1168-1175	2010

Kawamura Y, Ikeda K, Hirakawa M, Yatsuji H, Hosaka T, Sezaki H, Kobayashi M, Kobayashi M, <u>Suzuki F</u> , Suzuki Y, Arase Y, Kumada H.	Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients.	Am J Med	123	951-956	2010
Hashimoto Y, <u>Suzuki F</u> , Hirakawa M, Kawamura Y, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki Y, Kobayashi M, Arase Y, Ikeda K, Kumada H.	Clinical and virological effects of long-term (over 5 years) lamivudine therapy.	J Med Virol	82	684-691	2010
Suzuki Y, <u>Suzuki F</u> , Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Miyakawa Y, Kumada H.	Association of HLA-DR14 with Treatment Response in Japanese Patients with Autoimmune Hepatitis.	Dig Dis Sci	55	2070-2076	2010
瀬崎ひとみ, 鈴木文孝, 芥田憲夫, 平川美晴, 川村祐介, 八辻寛美, 保坂哲也, 小林正宏, 鈴木義之, 斎藤聡, 荒瀬康司, 池田健次, 熊田博光	C型慢性肝炎に対するヘグインターフェロンとリバビリン併用療法におけるNS3-4A プロテアーゼ阻害剤(Telaprevir)併用12週間治療のウイルス学的効の検討.	肝臓	51(7)	394-396	2010
八辻寛美, 鈴木文孝, 平川美晴, 川村祐介, 瀬崎ひとみ, 保坂哲也, 芥田憲夫, 小林正宏, 鈴木義之, 斎藤聡, 荒瀬康司, 池田健次, 岩崎里美, 峰田理恵, 綿引祥予, 小林万利子, 熊田博光	核酸アナログ未使用のB型慢性肝炎症例へのエンテカビル治療中にrtA181Tウイルスが増殖した一症例	肝臓	51(4)	196-198	2010
小林万利子, 鈴木文孝, 芥田憲夫, 鈴木義之, 瀬崎ひとみ, 八辻寛美, 保坂哲也, 小林正宏, 川村祐介, 平川美晴, 荒瀬康司, 池田健次, 峰田理恵, 岩崎里美, 綿引祥予, 中村祐輔, 茶山一彰, 熊田博光.	IL28B と HCV Core aa70 置換との関連	肝臓	51(6)	322-323	2010

<u>Suzuki F</u> , Suzuki Y, Akuta N, Sezaki H, Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Kamatani N, Nakamura Y, Chayama K, Kumada H.	Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.	Hepatology	53	415-21	2011
C Nelson H, Kobayashi M, Akuta N, <u>Suzuki F</u> , Kumada H, Abe H, Miki D, Imamura M, Ochi H, Katanamik N, Nakamura Y, Chayama K.	HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.	Gut	60	261-7	2011
Chayama K, C Nelson H, Abe H, Miki D, Ochi H, Karino Y, Toyota J, Nakamura Y, Kamatani N, Sezaki H, Kobayashi M, Akuta N, <u>Suzuki F</u> , Kumada H.	IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C.	J Infect Dis	204	84-93	2011
Arase Y, Suzuki Y, <u>Suzuki F</u> , Matsumoto N, Akuta N, Imai N, Seko Y, Sezaki H, Kawamura Y, Kobayashi M, Hosaka T, Saito S, Ikeda K, Kobayashi M, Kumada H.	Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients.	Interna Medicine	50	1-7	2011
Kobayashi M, Hosaka T, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Akuta N, <u>Suzuki F</u> , Suzuki Y, Saitoh S, Arase Y, Kumada H.	Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively.	Hepatol Res.	41	1036-45	2011

Arase Y, <u>Suzuki F</u> , Kawamura Y, Suzuki Y, Kobayashi M, Matsumoto N, Akuta N, Sezaki H, Hosaka T, Ogawa K, Imai N, Seko Y, Saito S, Ikeda K, Kobayashi M, Kumada H.	Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy.	Hepatology Res.	41	946-54	2011
Imai N, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, <u>Suzuki F</u> , Suzuki Y, Arase Y, Kumada H.	Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma.	Oncology	80	188-94	2011
Arase Y, <u>Suzuki F</u> , Kobayashi M, Suzuki Y, Kawamura Y, Matsumoto N, Akuta N, Kobayashi M, Sezaki H, Saito S, Hosaka T, Ikeda K, Kumada H, Ohmoto Y, Amakawa K, Tsuji H, Hsieh SD, Kato K, Tanabe M, Ogawa K, Hara S, Kobayashi T.	The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease.	Intern Med.	50	1081-7	2011
Akuta N, <u>Suzuki F</u> , Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.	Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.	J Med Virol	83	1016-22	2011
Ikeda K, Kobayashi M, Kawamura Y, Imai N, Seko Y, Hirakawa M, Hosaka T, Sezaki H, Akuta N, Saitoh S, <u>Suzuki F</u> , Suzuki Y, Arase Y, Kumada H.	Stage progression of small hepatocellular carcinoma after radical therapy: comparisons of radiofrequency ablation and surgery using the Markov model.	Liver Int.	31	692-9	2011

Arase Y, Suzuki F, Kobayashi M, Suzuki Y, Kawamura Y, Matsumoto N, Akuta N, Imai N, Kobayashi M, Sezaki H, Saito S, Hosaka T, Ikeda K, Kumada H, Ohmoto Y, Amakawa K, Tsuji H, Hsieh SD, Kobayashi T.	Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus.	Hepatol Res.	41	524-9	2011
Azakami T, Hayes CN, Sezaki H, Kobayashi M, Akuta N, Suzuki F, Kumada H, Abe H, Miki D, Tsuge M, Imamura M, Kawakami Y, Takahashi S, Ochi H, Nakamura Y, Kamatani N, Chayama K.	Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy.	J Med Virol	83	1048-57	2011
Imai N, Ikeda K, Seko Y, Matsumoto N, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Arase Y, Kumada H.	Transcatheter arterial chemotherapy with miriplatin for patients with hepatocellular carcinoma and chronic renal failure.	Nihon Shokakibyō Gakkai Zasshi	108	1872-8	2011
鈴木義之、瀬崎ひとみ、芥田憲夫、鈴木文孝、今井則博、平川美晴、川村祐介、保坂哲也、小林正宏、斎藤聡、荒瀬康司、池田健次、小林万利子、熊田博光	NS5A阻害剤とNS3プロテアーゼ阻害剤併用投与における早期抗ウイルス効果	肝臓	52	147-9	2011
保坂哲也、鈴木文孝、小林正宏、瀬古裕也、今井則博、平川美晴、川村祐介、瀬崎ひとみ、芥田憲夫、鈴木義之、斎藤聡、荒瀬康司、池田健次、小林万利子、熊田博光	B型慢性肝疾患に対する核酸アナログ療法によるHBs抗原消失とその関連因子の検討	肝臓	52	255-7	2011

小林万利子、鈴木文孝、鈴木義之、芥田憲夫、瀬崎ひとみ、川村祐介、瀬古裕也、保坂哲也、小林正宏、斎藤聡、荒瀬康司、池田健次、熊田博光	コバス TaqManHBV 「オート」 v2.0 における同一時の血清検体と血漿検体の HBVDNA 検出率の検討	肝臓	52	756-7	2011
Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Koyabashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada H.	Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment	Intervirolgy	55	417-425	2012
Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ohmoto Y, Amakawa K, Tsuji H, Kumada H.	Large-Scale Long-Term Follow-Up Study of Japanese Patients With Non-Alcoholic Fatty Liver Disease for the Onset of Hepatocellular Carcinoma.	Am J Gastroenterol	107	253-61	2012
Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada H.	Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy	Intervirolgy	55	231-241	2012
Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.	Complicated Relationships of Amino Acid Substitution in Hepatitis C Virus Core Region and IL28B Genotype Influencing Hepatocarcinogenesis	Hepatology	56	2134-2141	2012
Hanada K, Nakai K, Tanaka H, Suzuki F, Kumada H, Ohno Y, Ozawa S, Ogawa H.	Effect of Nuclear Receptor Downregulation on Hepatic Expression of Cytochrome P450 and Transporters in Chronic Hepatitis C in Association with Fibrosis Development	Drug Metab. Pharmacokinet.	27	301-306	2012

Suzuki F, Arase Y, Suzuki Y, Akuta N, Sezaki H, Seko Y, Kawamura Y, Hosaka T, Kobayabashi M, Saitoh S, Ikeda K, Kobayashi M, Kumada H.	Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan	J Gastroenterol	47	814-822	2012
Suzuki F, Sezaki H, Akuta N, Suzuki Y, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Watahiki S, Miyakawa Y, Kumada H.	Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b	J Clin Virol	54	352-354	2012
Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Kumada H.	Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients	J Hepatol	57	508-514	2012
Mori N, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kobayashi M, Kumada H.	Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection	J Gastroenterol	47	1022-1029	2012
Arase Y, Kawamura Y, Suzuki Y, Suzuki F, Akuta N, Matsumoto N, Seko Y, Sezaki H, Kobayashi M, Hosaka T, Hirakawa M, Saitoh S, Ikeda K, Kobayashi M, Kumada H.	Efficacy of reduction therapy of natural human β -interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 1b and high viral load	Hepatol Res	42	949-957	2012
Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.	Association of IL28B Genotype and Viral Response of Hepatitis C Virus Genotype 2 to Interferon Plus Ribavirin Combination Therapy	J Med Virol	84	1593-1599	2012

Takeyasu M, Akuta N, <u>Suzuki F</u> , Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.	Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma	J Med Virol	84	1199-1207	2012
Akuta N, <u>Suzuki F</u> , Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.	Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1	J Med Virol	84	1097-1105	2012
Matsumoto N, Arase Y, Seko Y, Imai N, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Kobayashi M, Suzuki Y, Saitoh S, <u>Suzuki F</u> , Ikeda K, Kumada H, Aida K, Kobayashi T.	Prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhosis with fasting plasma glucose level of < 126 mg/dl	Hepato Res	42	558-563	2012
Imai N, Ikeda K, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, <u>Suzuki F</u> , Suzuki Y, Arase Y, Kumada H.	Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma	Japanese Journal of Clinic	42	175-182	2012
Arase Y, Kobayashi M, <u>Suzuki F</u> , Suzuki Y, Kawamura Y, Akuta N, Imai N, Kobayashi M, Sezaki H, Matsumoto N, Saitoh S, Hosaka T, Ikeda K, Kumada H, Ohmoto Y, Amakawa K, Hsieh SD, Ogawa K, Tanabe M, Tsuji H, Kobayashi T.	Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients	Hepato Res	42	264-272	2012
Karino Y, Toyota J, Ikeda K, <u>Suzuki F</u> , Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Dennis Hernandez, Fei Yu, Fiona McPhee, Kumada H.	Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir	J Hepatol	2012.11.012	In press	2012

Suzuki Y, Ikeda K, <u>Suzuki F</u> , Toyota J, Karino Y, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Wenhua Hu, Timothy Eley, Fiona McPhee, Eric Hughes, Kumada H.	Dual Oral Therapy with Daclatasvir and Asunaprevir for Patients with HCV Genotype 1b Infection and Limited Treatment Options	J Hepatol	2012.09.037	In press	2012
Hosaka T, <u>Suzuki F</u> , Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.	Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection	Hepatology	10.1002	In press	2012
<u>Suzuki F</u> , Suzuki Y, Sezaki H, Akuta N, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Mineta R, Watahiki S, Kobayashi M, Nakayasu Y, Tsuda H, Aoki K, Yamada I, Kumada H.	Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon- α -2b and ribavirin in hepatitis C patients	Hepatol Res	10.1111	In press	2012
Tadokoro K, Kobayashi M, <u>Suzuki F</u> , Tanaka C, Yamaguchi T, Nagano M, Kumada H.	Comparative quantitative analysis of hepatitis C mutation at amino acids 70 and 91 in the core region by the Q-invader assay	J Virol Methods	10.1016/2012.10.011	In press	2012
Hosaka T, <u>Suzuki F</u> , Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.	Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study	J Gastroenterol	10.1007/0535-012-0688-7	In press	2012
Yamada I, <u>Suzuki F</u> , Kamiya N, Aoki K, Sakurai Y, Kanou M, Matsui H, Kumada H.	Safety, pharmacokinetics, and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection	J Viral Hepat	19	112-119	2012

Arase Y, Kobayashi M, Suzuki F, Suzuki Y, Kawamura Y, Akuta N, Kobayashi M, Sezaki H, Saitoh S, Hosaka T, Ikeda K, <u>Kumada H</u> , Kobayashi T.	Effect of type 2 diabetes on risk for malignancies included hepatocellular carcinoma in chronic hepatitis C	Hepatology	10.1002/26087	In press	2012
Seko Y, Ikeda K, Kawamura Y, Fukushima T, Hara T, Sezaki H, Hosaka T, Akuta N, <u>Suzuki F</u> , Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Kumada H.	Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma	Hepatology Res	10.1111/12041	In press	2013
今井則博、池田健次、瀬古裕也、原祐、大野敦司、松本直樹、川村祐介、保坂哲也、小林正宏、斎藤聡、瀬崎ひとみ、芥田憲夫、 <u>鈴木文孝</u> 、鈴木義之、荒瀬康司、熊田博光	ミリプラチン動注化学療法を併用したラジオ波凝固療法	肝臓	53(6)	351-354	2012
朝比奈靖浩、泉並木、桶谷眞、熊田博光、小池和彦、 <u>鈴木文孝</u> 、滝川一、田中篤、坪内博仁、林紀夫、平松直樹、四柳宏	C型肝炎治療ガイドライン(第1版) 日本肝臓学会肝炎診療ガイドライン作成委員会	肝臓	53(6)	355-395	2012
原祐、芥田憲夫、福島泰斗、瀬古裕也、川村祐介、瀬崎ひとみ、保坂哲也、小林正宏、斎藤聡、鈴木義之、 <u>鈴木文孝</u> 、荒瀬康司、池田健次、小林万利子、熊田博光	高齢者C型慢性肝炎に対するテラプレビル1500mg減量投与のパイロット・スタディ	肝臓	53(10)	624-626	2012
小関至、狩野吉康、豊田成司、高橋祥一、川上由育、茶山一彰、芥田憲夫、 <u>鈴木文孝</u> 、熊田博光	PEG-IFN/Ribavirin/Telaprevir三剤併用療法における薬剤投与率の抗ウイルス効果におよぼす影響	肝臓	53(2)	69-77	2012

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
	Q5. HBc抗体・HBs抗体のみが陽性の患者はどのような点に注意して診療すべきか？	泉並木 黒崎雅之	すべての内科医に役立つ肝疾患—なるほどQ&A	羊土社	東京	2011年	24-27
	Q13. B型肝炎硬変の症例にも、インターフェロンや核酸アナログの治療適応はあるか？	泉並木 黒崎雅之	すべての内科医に役立つ肝疾患—なるほどQ&A	羊土社	東京	2011年	51-53

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kiyohashi K, Nakagawa M et al.	Wnt5a Signaling Mediates Biliary Differentiation of Fetal Hepatic Stem/Progenitor Cells.	Hepatology	In press		2013
Nitta S, Nakagawa M, et al.	Hepatitis C virus NS4B protein targets STING and abrogates RIG-I-mediated type-I interferon-dependent innate immunity.	Hepatology	57	46-58	2013
Nakagawa M, et al.	Association of ITPA gene variation and serum ribavirin concentration with a decline in blood cell concentrations during pegylated interferon-alpha plus ribavirin therapy for chronic hepatitis C	Hepatol Int	Epub		2013
Kurosaki M Nakagawa M, et al.	Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C.	J Hepatol	56	602-608	2012
Kusano-Kitazume A, Nakagawa M, et al.	Identification of Novel N-(Morpholine-4-Carbon yloxy) Amidine Compounds as Potent Inhibitors against Hepatitis C Virus Replication.	Antimicrob Agent Chemother	56	1315-23	2012
Kurosaki M, Nakagawa M, et al.	Age and total ribavirin dose are independent predictors of relapse after interferon therapy in chronic hepatitis C revealed by data mining analysis.	Antiviral Therapy	17	35-43	2012

Ueyama M, <u>Nakagawa M</u> (equal contribution), et al.	Serum interleukin-6 levels can predict resistance to treatment of chronic hepatitis C infection with pegylated-interferon alpha 2b plus ribavirin.	<i>Antiviral Therapy</i>	16	1089-1091	2011
Sakamoto N, <u>Nakagawa M</u> (equal contribution), et al.	Association of IL28B polymorphism with response to pegylated-interferon alpha plus ribavirin combination therapy in patients with chronic genotype 2 hepatitis C.	<i>J Medical Virol</i>	83	871-878	2011
Funaoka Y, <u>Nakagawa M</u> , et al.	Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91.	<i>J Virol</i>	85	5986-94	2011
Kurosaki M, <u>Nakagawa M</u> , et al.	Pretreatment Prediction of Response to Pegylated-Interferon Plus Ribavirin for Chronic Hepatitis C using Genetic Polymorphism in IL28B and Viral Factors.	<i>J Hepatol</i>	54	439-48	2011
Watanabe T, <u>Nakagawa M</u> , et al.	Inhibitory effect of triterpenoid compound with or without interferon-alpha on Hepatitis C virus infection.	<i>Antimicrob Agent Chemother</i>	55	2537-45.	2011
Onozuka I, <u>Nakagawa M</u> , et al.	Cholestatic liver fibrosis and toxin-induced fibrosis are exacerbated in matrix metalloproteinase-2 deficient mice.	<i>Biochem Biophys Res Commun</i>	406	134-140	2011
Yamamoto M, <u>Nakagawa M</u> , et al.	Studies on virus kinetics using infectious fluorescence-tagged hepatitis C virus cell culture.	<i>Hepatology Res</i>	41	258-69	2011
Kurosaki M, <u>Nakagawa M</u> , et al.	Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis.	<i>J Medical Virol</i>	83	445-52	2011
Ueyama M, <u>Nakagawa M</u> (equal contribution), et al.	Serum interleukin-6 levels can predict resistance to treatment of chronic hepatitis C infection with pegylated-interferon alpha 2b plus ribavirin.	<i>Antiviral Therapy</i>	16	1089-1091	2011

Sakamoto N, Nakagawa M(equal contribution), et al.	Association of IL28B polymorphism with response to pegylated-interferon alpha plus ribavirin combination therapy in patients with chronic genotype 2 hepatitis C.	J Medical Virol	83	871-878	2011
Nakagawa M, Sakamoto N (equal contribution)	Mutations in the Interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection.	J.Gastroenterology	45	656-65	2010
Karakama Y Nakagawa M, et al.	Inhibition of HCV replication by a specific inhibitor of serine-arginine-rich protein kinase.	Antimicrobial Agents and Chemotherapy	54	3179-3186	2010
Suda G Nakagawa M, et al.	IL-6-mediated intersubgenotypic variation of interferon sensitivity in hepatitis C virus genotype 2a/2b chimeric clones.	Virology	407	80-90	2010
Sakamoto N Nakagawa M, et al.	ITPA gene variant protects against anemia induced by pegylated interferon-a and ribavirin therapy for Japanese patients with chronic hepatitis C.	Hepatology Res	40	1063-1071	2010
中川美奈、坂本直哉、渡辺守	Cyclophilin inhibitors	肝胆膵	62巻2号	403-411	2011
植山真由美、中川美奈、坂本直哉、渡辺守	ホルモン・サイトカインから見た肝発癌機構の性差 IL-6と肝炎・肝発癌	肝胆膵	60巻5号	849-856	2010
中川美奈、坂本直哉	C型肝炎治療における治療効果予測と副作用対策	消化器の臨床	15巻3号	278-284	2012
中川美奈、坂本直哉	HCV治療抵抗性関連遺伝子の同定と治療展開	G.I.Research	6巻	17-21	2012
中川美奈、坂本直哉、渡辺守	Cyclophilin inhibitors	肝胆膵	62巻2号	403-411	2011
村川美也子、中川美奈、坂本直哉	宿主側因子 (ITPA, SNPs)	診断と治療		71-73	2012

研究成果の刊行に関する一覧表レイアウト

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Chang J-H, Kato N, et al.	Double-stranded-RN A activated protein kinase inhibits hepatitis C virus replication but may be not essential in interferon treatment.	Liver Int	30	311-318	2010
加藤直也、他.	今後有望なウイルス肝炎の新規治療薬.	medicina	47 巻 3 号	2010-2013	2010
加藤直也、他.	C 型肝炎の近未来治療 .	Medical Science Digest	36 巻 8/号	916-919	2010
Kumar V, Kato N, et al.	Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma.	Nat Genet	43	455-458	2011
加藤直也、他	GWAS による C 型肝炎感受性遺伝子の同定	肝胆膵	62 巻 5 号	919-925	2011
加藤直也.	肝発癌の分子機構	The Liver Cancer Journal	3 巻	15-25	2011
加藤直也、他	C 型肝炎の GWAS 研究 : MICA SNP	肝胆膵	62 巻 12 号	1045-1051	2011
加藤直也、他	新規薬剤(新規プロテアーゼ阻害薬, IFN λ など)	医学のあゆみ	239 巻	1175-1181	2011

Kumar V, Kato N, et al.	Soluble MICA and a MICA variation as possible prognostic biomarkers for HBV-induced hepatocellular carcinoma.	PLoS One	7	e44743	2012
Urabe Y, Kato N, et al.	A genome-wide association study of HCV induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at MHC region.	J Hepatol			2013 (in press)
Lo PHY, Kato N, et al.	Identification of a functional variant in the MICA promoter which regulates MICA expression and increases HCV-related hepatocellular carcinoma risk.	PLoS One			2013 (in press)
加藤直也、他	新規抗ウイルス薬の開発動向と展望 新規抗肝炎ウイルス薬 新規抗HCV薬	日本臨牀	70 巻 4 号	664-670	2012
加藤直也、他	プロテアーゼ阻害薬以外の新規HCV治療薬の開発状況	Mebio	29 巻 8 号	75-81	2012
加藤直也、他	HCV 感染の GWAS 解析	肝 疾 患 Review 2012-2013		108-112	2012

研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表雑誌	巻	ページ	出版年
1) Mori K, (加藤)	Gene expression profile of Li23, a new human hepatoma cell line that enables robust hepatitis C virus replication: Comparison with HuH-7 and other hepatic cell lines.	Hepatology Research	40	1248-1253	2010
2) Ikeda F, (加藤)	Amino acid substitutions of hepatitis C virus core protein are not associated with intracellular antiviral response to interferon- α in vitro.	Liver International	30	1324-1331	2010
3) Nozaki A, (加藤)	Hydroxyurea as an inhibitor of hepatitis C virus RNA replication.	Archives of Virology	155	601-605	2010
4) Nozaki A, (加藤)	Hydroxyurea Suppresses Hepatitis C Virus Replication in Human: A Phase I Trial of Oral Hydroxyurea in Chronic Hepatitis C Patients. Antiviral Therapy.	Antiviral Therapy	15	1179-1183	2010
5) Nakamura N, (加藤)	An antioxidant resveratrol significantly enhanced replication of hepatitis C virus.	World Journal of Gastroenterology	16	184-192	2010
6) Shigoka M, (加藤)	Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development.	Pathology International	60	351-357	2010
7) Yu S, (加藤)	Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon	Journal of General Virology	91	2080-2090	2010

	regulatory factor 3 activation and dampening of the interaction between TBK1/IKKepsilon and DDX3.				
8)Tanaka T, (加藤)	Generation of single-chain Fvs against detergent-solubilized recombinant antigens with a simple coating procedure.	Journal of Bioscience and Bioengineering	110	374-376	2010
9)Oshiumi H, (加藤)	Hepatitis C virus core protein abrogates the DDX3 function that enhances IPS-1-mediated IFN- α induction	PLoS One	5	e14258	2010
10)Ariumi Y, (加藤)	The ESCRT system is required for hepatitis C virus production.	PLoS One	6	e14517	2011
11)Wen X, (加藤)	Elimination of hepatitis C virus from hepatocytes by a selective activation of therapeutic molecules.	PLoS One	6	e15967	2011
12)Mori K, (加藤)	Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system.	Virus Research	151	61-70	2011
13)Ikeda M, (加藤)	Anti-ulceragent teprenone inhibits hepatitis C virus replication: potential treatment for hepatitis C	Liver International	31	871-880	2011
14)Ariumi Y, (加藤)	Hepatitis C virus hijacks P-body and stress granule components around lipid droplets.	Journal of Virology	85	6882- 6892	2011
15)Ueda Y, (加藤)	Plural assay systems derived from different cell lines and hepatitis C virus strains are required for the objective evaluation of anti-hepatitis C virus reagents.	Biochemical and Biophysical Research Communication	409	663-668	2011
16)Takeshita S, (加藤)	Geranylgeranylacetone has anti-hepatitis C virus activity via	Journal of Gastroenterology	47	195-201	2012

	activation of mTOR in human hepatoma cells.	gy			
17)Mori K, (加藤)	Development of a drug assay system with hepatitis C virus genome derived from a patient with acute hepatitis C.	Virus Genes	44	374-381	2012
18)Sejima H, (加藤)	Identification of host genes showing differential expression profiles with cell-based long-term replication of hepatitis C virus RNA.	Virus Research	167	74-85	2012
19)Takeda M, (加藤)	Development of hepatitis C virus production reporter assay systems using two different hepatoma cell lines.	Journal of General Virology	93	1422-1431	2012
20)Takeda M, (加藤)	Raloxifene inhibits hepatitis C virus infection and replication.	FEBS Open Bio	2	279-283	2012
21)Marozin S, (加藤)	Post-translational modification of VSV glycoprotein, but not JNK inhibition, is the antiviral mechanism of SP600125.	Journal of Virology	86	4844-4855	2012
22)Iikura M, (加藤)	ENT1, a ribavirin transporter, plays a pivotal role in antiviral efficacy of ribavirin in a hepatitis C virus replication cell system.	Antimicrobial Agents and Chemotherapy	56	1407-1413	2012
23)Yamashita A, (加藤)	Inhibition of hepatitis C virus replication and viral helicase by ethyl acetate extract of the marine feather star	Marin Drugs	10	744-761	2012

	Alloeocomatella polycladia.				
24)Fujimoto Y, (加藤)	Inhibition of both protease and helicase activities of hepatitis 1 C virus NS3 by an ethyl acetate extract of marine sponge Amphimedon sp.	PLoS One	7	e48685	2012
25)Koike K, (加藤)	Eradication of hepatitis C virus subgenomic replicon by interferon results in aberrant retinol related protein expression.	Acta Medica Okayama	66	461-468	2012
26)Kuroki M, (加藤)	PML tumor suppressor protein is required for HCV production.	Biochemical and Biophysical Research Communications	430	592-597	2013

研究成果の刊行に関する一覧表レイアウト (参考)

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kanda T, Wu S, Kiyohara T, Nakamoto S, Jiang X, Miyamura T, Imazeki F, Ishii K, Wakita T, <u>Yokosuka O.</u>	Interleukin-29 suppresses hepatitis A and C viral internal ribosomal entry site- mediated translation.	Viral Immunol.	25(5)	379-86.	2012
Miyamura T, Kanda T, Nakamoto S, Wu S, Jiang X, Arai M, Fujiwara K, Imazeki F, <u>Yokosuka O.</u>	Roles of ITPA and IL28B Genotypes in Chronic Hepatitis C Patients Treated with Peginterferon Plus Ribavirin.	Viruses.	4 (8)	1264-78.	2012
Wu S, Kanda T, Imazeki F, Nakamoto S, Tanaka T, Arai M, Roger T, Shirasawa H, Nomura F, <u>Yokosuka O.</u>	Hepatitis B virus e antigen physically associates with receptor-interacting serine/ threonine protein kinase 2 and regulates IL-6 gene expression.	J Infect Dis.	6(3)	415-20.	2012
Yan J, Kanda T, Wu S, Imazeki F, <u>Yokosuka O.</u>	Hepatitis A, B, C and E virus markers in Chinese residing in Tokyo, Japan.	Hepatol Res.	42 (10)	974-81.	2012
Arai M, Togo S, Kanda T, Fujiwara K, Imazeki F, <u>Yokosuka O.</u>	Quantification of hepatitis B surface antigen can help predict spontaneous hepatitis B surface antigen seroclearance.	Eur J Gastroenterol Hepatol.	24 (4)	414-8.	2012
Maroka D, Imazeki F, Arai M, Kanda T, Fujiwara K, <u>Yokosuka O.</u>	Longitudinal changes of the laboratory data of chronic hepatitis C patients with sustained virological response on long-term follow-up.	J Viral Hepat.	19 (2)	E97-e104.	2012
Kanda T, Shinozaki M, Kamezaki H, Wu S, Nakamoto S, Arai M, Fujiwara K, Goto N, Imazeki F, <u>Yokosuka O.</u>	Efficacy of lamivudine or Entecavir on acute exacerbation of chronic hepatitis B.	Int J Med Sci.	9 (1)	27-32.	2012